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ABSTRACT 
Background and Aims: Although a potential benefit of drinking green tea has been 
suggested to reduce the development of cardiovascular disease, no study has 
investigated the relationship between plasma tea catechin and risk of cardiovascular 
disease. 
Methods: A prospective, nested case-control study was conducted to examine the 
association between plasma tea catechin and risk of stroke and coronary heart disease 
(CHD) in a cohort of 29,876 men and women aged 40–69 years without history of heart 
disease, stroke or cancer. Participants completed a survey and donated blood samples 
between 1990 and 1994, and followed-up through 2008. A total of 1,132 stroke cases 
and 209 CHD cases, matched 1:1 to controls (n=1,132) for stroke and 1:2 to controls 
(n=418) for CHD, were included in the analysis. 
Results: We found no significant association between plasma tea catechin and the 
incidence of stroke or CHD in either men or women. However, we found that high 
plasma levels of epigallocatechin gallate (EGCG) were associated with reduced risk of 
stroke in non-smoking men; the adjusted odds ratio (95% CI) for the highest vs. non-
detectable levels was 0.53 (0.29–0.98). The respective OR in male smokers was 1.23 
(0.75–2.16). A significant interaction by smoking status was found for the highest vs. 
non-detected plasma EGCG in relation to stroke (p-for-interaction: p=0.09).   
Conclusions: Plasma tea catechin was not associated with reduced risks of either stroke 
or CHD, while a protective effect of certain tea catechin on stroke risk is suggested for 
male non-smokers.  
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Introduction 
Because of its high content of catechins (epicatechin (EC), epicatechin gallate (ECG), 
epigallocatechin (EGC) and epigallocatechin gallate (EGCG)), tea consumption has 
been suggested to protect against the development of cardiovascular disease (CVD) [1].  
 Several large-scale epidemiological studies have examined the relationship 
between tea consumption and CVD [2-4]. With regard to stroke, a pooled meta-analysis 
reported that tea drinking, without any confined effect to black or green tea; was 
associated with reduced mortality and morbidity of stroke [5]. Indeed, subjects drinking 
three or more cups of tea per day had a 21% reduced risk of fatal or non-fatal stroke 
events.5 Our prospective cohort study of Japanese subjects [6] showed that drinking four 
or more cups of green tea per day was associated with a 20% lower risk of stroke over 
13 years of follow-up. Nevertheless, these studies assessed green tea intake based on a 
self-administered questionnaire or in-person interview [5, 6]. No study has directly 
measured pre-diagnostic biomarkers of tea catechins, or examined the risk of stroke in 
relation to plasma tea catechin levels. 
The mechanisms underlying the association between tea catechins and risk of 
CVD have not been well elucidated, although plausible explanations include the 
inhibition of oxidative stress and an anti-inflammatory response via antioxidant and free 
radical scavenging properties [7] which in turn may inhibit hydrogen peroxide, lipid 
peroxidation, and apoptotic cells [8, 9]. This may result in improved endothelial 
function [10], inhibition of platelet aggregation [11], and induction of blood vessel 
relaxation, which lowers blood pressure, and prevents overgrowth of smooth muscle 
cells in blood vessel walls [12], which can otherwise narrow the blood vessel, reducing 
blood flow and increasing blood pressure levels. Therefore, considering that anti-
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inflammatory catechins represent 80–90% of the total catechins in green tea [13, 14], it 
is reasonable to assume that green tea would have a beneficial effect on the 
cardiovascular system. 
The catechin content of green tea varies by preparation, type and amount of 
green tea leaves, water temperature, brewing time, and other factors. To reduce 
misclassification because of the above variables as well as to further understand the role 
of tea catechins in the etiology of CVD, it is worth examining this association using pre-
diagnostic biomarkers of tea catechins. Therefore, we evaluated the association between 
levels of plasma tea catechins and the risk of stroke and coronary heart disease (CHD) 
in a large nested-case control study among approximately 30,000 subjects who provided 
blood samples during a large prospective cohort of the Japan Public Health Center-
based Prospective Study (JPHC Study). 
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MATERIALS AND METHODS 
Study population 
The first cohort of the Japan Public Health Center-based Prospective Study (JPHC 
Study) was initiated in 1990 (Cohort I) and the second in 1993 (Cohort-II) in 11 public 
health center areas throughout Japan [15]. Two public health center areas (Tokyo and 
Osaka) were excluded from the present study because data on the incidence of CVD 
were not available. The study population of the present study was defined as all 
residents (n = 116,896) aged 40–59 years for Cohort I and 40–69 years for Cohort II at 
baseline. Of these, 220 were excluded because of non-Japanese nationality (n = 51), late 
report of emigration occurring before the start of the follow-up period (n = 166), and 
incorrect birth date (n = 3), leaving 116,676 residents eligible for the study. The present 
study was approved by the institutional review boards of the National Cancer Center, 
and Osaka University. 
 
Baseline questionnaire survey and blood collection 
A baseline self-administered questionnaire on various aspects of lifestyle was presented 
to participants in 1990 for Cohort I and in 1993 and 1994 for Cohort II. The overall 
response rate was 82%, giving 95,374 respondents who were included in the study 
cohort. The questionnaire covered personal and family medical history; psychosocial 
factors, such as perceived mental stress; household structure; occupation; behavioral 
patterns; and lifestyle factors, such as smoking and alcohol habits, dietary habits, and 
physical activity.  
Among the study subjects, 34,085 residents donated 10 mL samples of venous 
blood. Samples were collected into vacutainer tubes containing heparin at the time of 
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health examinations conducted by the respective municipal governments during the 
same year as the baseline survey. They were divided into plasma and buffy layers and 
stored at −80°C until analysis. Of all blood samples, 41% were obtained during fasting 
i.e. 8 hr or more since the last meal. The mean time difference between the baseline 
survey and blood sample collection was 9.6 months. 
 
Confirmation of stroke and coronary heart disease 
We followed study subjects until December 31, 2007. Those who had died or moved to 
other municipalities were identified annually through residential registries in their 
Public Health Center area. Among the study subjects, 9.9% moved away and 0.2% were 
lost to follow-up during the study period.  
A total of 81 hospitals were registered within the administrative districts of the 
JPHC cohort. All are major hospitals with the capability of treating patients with stroke 
and acute myocardial infarction (MI). Physicians blinded to patient lifestyle data 
reviewed medical records at each hospital. Stroke and acute MI events were included in 
the study if they firstly occurred after the date of return of the baseline questionnaire 
and before January 1, 2008.  
Stroke was confirmed according to the criteria of the National Survey of Stroke 
[16], which requires the presence of focal neurological deficits of sudden or rapid onset 
lasting at least 24 hours or until death. Strokes were further classified as hemorrhagic 
stroke (subarachnoid or intraparenchymal), or ischemic stroke (thrombotic or embolic). 
All registered hospitals were equipped with computer tomographic scans and/or 
magnetic resonance scans. A definite diagnosis was established mainly based on an 
examination of computer tomographic or magnetic resonance images and/or autopsy. 
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MI was confirmed in the medical records in accordance with the criteria of the 
MONICA (Monitoring Trends and Determinants of Cardiovascular Disease) project 
[17], which requires evidence in the form of electrocardiograms, cardiac enzymes, 
and/or autopsy. In the absence of a diagnosis of MI, deaths that occurred within 1 hour 
from the onset of symptoms were regarded as sudden cardiac deaths. MI and sudden 
cardiac deaths were regarded as coronary heart disease. 
 
Selection of case and control subjects 
During the study period, a total of 1,132 strokes and 209 CHD occurred among the 
29,876 subjects who had returned the baseline questionnaire, reported no prior history 
of MI, angina pectoris, stroke, or cancer, and provided blood samples.  
According to a power calculation, when the percentage of persons with an 
exposure factor in the control group is set to 0.75, 212 (case/control ratio = 1), 159 
(case/control ratio = 2) cases are needed to have a power of 80%, with alpha 5%, to 
detect an odds ratio of 2.0. For a sufficient number of samples, one control case for each 
case of stroke and two for each case of CHD were selected using incidence-density 
sampling [18]. Controls were matched with cases by sex, age (within 2 years), date of 
blood sampling (within 3 months), time since last meal (within 4 hr) and study location 
(Public Health Center area). Thus, 1,132 cases and matched 1,132 controls were 
included in the analysis for stroke, and 209 cases and matched 418 controls were 
included in the analysis for CHD. 
Laboratory assays 
Plasma levels of EC, ECG, EGC and EGCG were analyzed using high-performance 
liquid chromatography with a coulometric array detector in accordance with the 
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modified methods of Lee et al [19, 20]. Plasma concentrations of tea catechins were 
determined by linear regression of the peak height for each standard, and adjusted 
according to the recovery rate of the internal plasma standard. The regression 
coefficient of peak height and concentration calculated for tea catechins revealed a 
linearity range 0–0.5 µg/mL, with correlation coefficient values >0.998. The 
voltammetric response for the standard solution displayed coefficients of variation of 
10% for intra- and 11% for inter-day variation. Recovery rates of tea catechins in 
plasma samples ranged between approximately 63 and 90% (EC, 89%; ECG, 63%; 
EGC, 90%; and EGCG, 66%). In the present study, tea catechins were measured in two 
different years (i.e., 2004 and 2008). The minimum detected values are 0.008 µg/mL for 
EC, 0.002 µg/mL for ECG, 0.004 µg/mL for EGC, and 0.009 µg/mL for EGCG for 
2004 and those for 2008 are 0.0006, 0.001, 0.001, and 0.0007 µg/mL, respectively. All 
analyses of tea catechins were performed at the National Cancer Center, Japan, as 
described previously [21]. High-sensitivity C-reactive protein (hs-CRP) levels were 
measured using an ultra-sensitive latex-enhanced immunoassay with an automatic 
analyzer (BN Prospec nephlomete, Dade Behring, Newark, DE, USA) at Kotobiken 
Medical Laboratory, Tsukuba, and Osaka Medical Center for Health Science and 
Promotion. All laboratory personnel were blinded with respect to case or control status.  
 
Statistical analysis 
The Wilcoxon–Mann Whitney test was used to compare mean values of baseline 
cardiovascular risk factors with non-normally distributed values, and chi-square test was 
used to compare proportions.  
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Conditional odds ratios (OR) and 95% confidence intervals (95% CI) of stroke and 
CHD were estimated according to categories for tea catechins using a conditional 
logistic regression model. The proportions of subjects with detectable levels of EGC, 
EGCG, ECG and EC were 43%, 40%, 33%, and 42%, respectively (shown in a 
supplemental figure1). Since the minimum detected values of tea catechins were 
different at the two measured time points (at the years 2004 and 2008), the detected 
values of each individual catechin and of total catechin (EGC, EGCG, ECG, plus EC) 
divided by the tertile of the stroke controls and the median of the CHD controls at each 
measured time point, used a non-detected level as a reference category. We only 
adjusted for covariates that were associated with stroke or CHD at a significance level 
of p<0.05 in our study sample, including systolic blood pressure (mmHg), anti-
hypertensive medication use (yes vs. no), body mass index (BMI; kg/m2), alcohol intake 
(non-current drinker, occasional drinker, current drinker), smoking status (current 
smoker, past smoker, never smoker), diabetic category (normal, borderline or diabetes 
mellitus), and quartiles of hs-CRP (mg/L). Borderline diabetes mellitus was defined as a 
fasting glucose level of 6.1–6.9 mmol/L or non-fasting level of 7.8–11.0 mmol/L. 
Diabetes mellitus was defined as a fasting glucose level of >7.0 mmol/L, a non-fasting 
level of >11.1 mmol/L, or the use of medication for diabetes. 
To check for effect modification, we also stratified analyses according to smoking 
status (current smoker and non-smoker). All analyses were conducted using the SAS 
statistical package version 9.1 (SAS Institute Inc., Cary, NC). Statistical differences 
were considered statistically significant if p values were <0.05 (two-tailed significance 
levels).  
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RESULTS 
Table 1 shows the sex-specific risk characteristics of stroke and CHD cases and their 
controls. For men, the average age at the baseline survey from 1990 to 1994 was 56-57 
years for both stroke and CHD cases and controls. The prevalence of current smoking, 
anti-hypertensive medication use, and diabetes mellitus was higher for both stroke and 
CHD cases than their controls while the prevalence of heavy drinking was lower for 
CHD cases than for controls. Mean values of systolic blood pressure were also higher 
for stroke and CHD cases than their controls. Mean values of BMI, total cholesterol and 
hs-CRP was higher for CHD cases than controls.  
For women, the average age at the baseline was 57-59 years for both stroke and 
CHD cases and controls. The prevalence of anti-hypertensive medication use was higher 
for both stroke and CHD cases than their controls while the prevalence of current 
smoking, diabetes mellitus was higher only for stroke cases than for controls. Mean 
values of systolic blood pressure were also higher for stroke and CHD cases than their 
controls. Mean values of total cholesterol was higher for stroke cases than for controls, 
while hs-CRP was higher for CHD cases than controls.  
The correlation coefficients between the plasma tea catechin levels and green 
tea intake are shown in Table 2, and range between 0.14 for ECG and 0.36 for EGC.  
Table 3 shows age, sex, date of blood sampling, and time since last meal-
matched and multivariable-adjusted conditional odds ratio (95% CI) for stroke and 
CHD according to the levels of plasma tea catechins (i.e., EGC, EGCG, ECG, EC, and 
total catechin). We found no significant trends between plasma tea catechins and the 
incidence of stroke or CHD in either men or women.  
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We next checked for potential effect modification by stratifying the analyses by 
smoking status (being and not being a current smoker). Compared with the non-detected 
plasma EGCG levels, the highest plasma levels of EGCG were associated with a 
reduced risk of stroke in male non-smokers; the adjusted OR (95% CI) was 0.53 (0.29–
0.98) (Table 4). The respective OR in male smokers was 1.23 (0.75–2.16). A significant 
interaction by smoking status was found for the highest vs. non-detected plasma EGCG 
levels in relation to stroke (p for interaction: p=0.09).  
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DISCUSSION 
In this population-based prospective nested-case control study in Japanese subjects, we 
found no associations between the levels of plasma tea catechins and risk of stroke and 
CHD. However, we found a significant interaction between smoking status, the 
association between plasma EGCG and the risk of stroke in men. Male non-smokers 
with the highest levels of plasma EGCG compared with those with non-detectable 
levels had a reduced risk of stroke, while no association was found in male smokers. 
 Tea catechins in plasma are partially varied by individual absorption and 
metabolism, and further differ because of individual tea drinking styles. Of the catechins 
in a cup of green tea prepared using 1 g of tea leaves brewed for 3 minutes in 100 mL of 
hot water, EGCG is known to be the most abundant extracted catechin (48–55%) 
followed by EGC (9–12%), ECG (9–12%) and EC (5–7%) [13, 22]; however, plasma 
EGCG concentrations account for only 2% of the ingested amount in healthy people 
[23]. In the present study, the correlation coefficient between the plasma levels of 
EGCG and green tea intake was low (r = 0.21–0.28 for men and r = 0.25–0.28 for 
women). However, catechins are widely distributed in fruits, vegetables, and other 
drinks (i.e., black and oolong tea) [24] and their plasma levels may thus also be affected 
by these food products. This may help to explain the apparently low correlation between 
green tea intake and plasma levels of catechin in the present study. Despite their low 
bioavailability, previous in vivo reports suggest that absorbed catechins may exert 
beneficial effects [25].  
A daily injection of EGCG (200 mg/kg) for 3 weeks improved endothelial function 
and reduced systolic blood pressure in hypertensive rats [26]. Furthermore, the 
progression of atherosclerotic plaque formation was reduced in hypercholesterolemic 
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apolipoprotein E-deficient mice treated with an EGCG (10 mg/kg) daily injection for 6 
weeks [27]. A randomized crossover study of 20 healthy male smokers reported a 
significant improvement of endothelium dependent vasodilatation as well as a decrease 
in urinary 8-iso prostaglandin F2α, a biomarker of oxidative stress, after consumption of 
green tea (400 mL) containing 61.8 mg/dL of EGCG [28]. This decrease in urinary 8-iso 
prostaglandin F2α was also found in seven healthy non-smokers [28]. In the present 
study, we found a significantly reduced risk of stroke associated with the highest vs. 
non-detectable plasma levels of EGCG in male non-smokers (despite no association 
being found for total subjects). EGCG has the strongest anti-oxidative activity among 
the green tea catechins (EC, ECG, EGC, and EGCG) [29], and its putative beneficial 
effect on cardiovascular disease is exerted through an oxidative stress-related pathway 
[30]. However, cigarette smoke exposure increases oxidative stress as a potential 
mechanism promoting cardiovascular disease [31], and cigarette smoking may thus 
modify the catechin–cardiovascular disease relationship.  
Furthermore, increasing evidence suggests that manipulation of the gut microbiota 
composition is associated with cardiovascular health [32]. A previous study showed that 
flavan-3-ol (catechins, proanthocyanidins) modulated the microbiota composition and 
its catabolic activity, inducing changes that could in turn affect the bioavailability and 
potential bioactivity of these compounds [33]. The gut microbiota biotransforms flavan-
3-ol to bioactive metabolites [34], and these microbe-derived phenolic metabolites have 
been reported to exert beneficial cardiovascular health effects via antioxidant [35], anti-
inflammatory [36], and antithrombotic activities [37]. The conjugated microbial 
bioconversion products of catechins have been reported to have higher biological 
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activity than catechins per se [34], which might help to explain why the measured 
catechins were not generally associated with cardiovascular risk in the present study.  
Many of the investigations to date suggest that higher consumption of green and 
black tea does prevent the development of CVD [6, 38-40], despite the null results from 
some studies [39-40]. However, the present study is the first to provide a more direct 
test of this hypothesis by looking at the association between plasma tea catechin levels 
and the risk of CVD under a prospective nested-case control study in an Asian 
population, in which green tea is a primary drink. We did not find associations between 
levels of plasma tea catechins and the risk of either stroke or CHD. However, we found 
some evidence of reduced risks of stroke associated with plasma EGCG among male 
non-smokers.   
The present study has several potential limitations. First, although the study 
subjects were selected from a general population sample, only 38% of subjects provided 
blood samples at baseline. According to a previous JPHC report, subjects with and 
without baseline blood samples differed in socioeconomic status and lifestyle profile; 
those who provided a sample smoked less, showed greater participation in physical 
exercise, and had a higher intake of green vegetables and fruits [41]. Given the 
difficulty of extrapolating risk estimates for our sub-cohort to an entire cohort, any 
extrapolation of the present results to the general population thus needs to be undertaken 
with care.  
Second, a large percentage of subjects was not having a detectable level of 
catechins. The plasma levels of tea catechins are affected by time elapsed since the last 
meal because the plasma half-life is approximately 5 hr for EGCG and approximately 
2.5 hr for EGC and EC [42]. We therefore matched fasting time between cases and 
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controls to minimize the attenuation of risk estimates derived from this measurement 
error. Furthermore, previous studies found correlations between dietary intake and 
serum or plasma levels of α- and β-carotene of 0.25–0.58 and 0.15–0.36, respectively 
[43], indicating that the low bioavailability of tea catechins in the present study may be 
reasonable. 
Third, we measured plasma tea catechins only once for each individual, though 
blood and urine levels of tea catechins have shown considerable interindividual 
variation [44-45]. However, green tea consumption levels by most individuals are 
assumed to be relatively stable over time in Japan, with high reproducibility among 
repeated measurements of green tea intake by Food Frequency Questionnaire 
(correlation coefﬁcient = 0.64 for 1-year interval and 0.54 for 5-year interval) 
(unpublished data). 
 The strengths of our study are its prospective population-based design and status 
as the largest nested case-control study of this association, which yielded good 
statistical power in detecting the effects of tea catechins. Although there were a 
sufficient number of samples, our findings may be limited because of the small number 
of CHD cases. Thus, further research is needed to assess the repeatability of the 
association between the levels of plasma tea catechins and risk of CHD with a larger 
number of cases.  
Ours is the first investigation of plasma tea catechins and risks of stroke and 
CHD incidences. The present study found no associations between plasma levels of tea 
catechin and risks of stroke and CHD among the subjects overall. However, plasma 
EGCG levels were associated with a possible reduced risk of stroke among male non-
smokers, suggesting that tea could be a useful component of a healthy diet. 
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Table 1. Characteristics of case and matched control subjects at baseline 
  Men   Women 
  
Stroke case  
n=583 
Stroke control 
 n=583 
P for 
difference 
  
Stroke case 
 n=549 
Stroke control 
 n=549 
P for 
difference 
Age, year 57.4 57.3 0.80   57.2 57.1 0.82 
Body mass index, kg/m2 23.7 23.5 0.18   24.6 24.0 0.003 
Current smoker,% 50.0 40.3 <0.001   5.85 2.37 0.004 
Heavy alcohol intake (≥450mg/week),% 71.8 65.9 0.04   7.22 7.92 0.67 
Systolic blood pressure, mmHg 141.7 134.1 <0.001   139.0 132.1 <0.001 
Antihypertesive drug use,% 26.4 14.9 <0.001   31.3 17.3 <0.001 
Diabetes mellitus,% 11.9 5.14 <0.001   8.77 4.48 0.01 
Serum total cholesterol levels, mmol 194.6 193.3 0.54   209.6 205.1 0.04 
hs-CRP, mg/l 1.74 1.22 0.08   1.16 1.11 0.73 
Green tea intake, g/day 440.1 457.5 0.39   402.8 399.7 0.87 
Chinese tea intake, g/day 35.5 40.7 0.49   58.1 53.3 0.63 
Black tea intake, g/day 11.6 9.7 0.53   11.3 11.3 1.00 
Fruit juice intake, g/day 23.5 26.7 0.33   27.1 24.7 0.53 
Vegetable juice intake, g/day 14.6 12.5 0.45   13.9 15.7 0.62 
Vegetable intake, g/day 114.3 113.6 0.90   127.0 131.6 0.46 
Green and yellow vegetable, g/day 29.9 30.5 0.62   38.3 38.0 0.83 
Fruit intake, g/day 73.3 79.7 0.15   109.3 109.8 0.93 
 Hs-CRP: high-sensitivity C-reactive protein 
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Table 2. Spearman correlation coefficients between green tea consumption (g/week) and ordinal categories of plasma tea catechina  
Stroke Men    Women  
 r p--value   r p--value 
EGC  0.36 <0.001  EGC 0.34 <0.001 
EC 0.27 <0.001  EC 0.27 <0.001 
EGCG 0.28 <0.001  EGCG 0.28 <0.001 
ECG 0.27 <0.001  ECG 0.24 <0.001 
Total catechin  0.31 <0.001  Total catechin  0.31 <0.001 
CHD       
EGC  0.23 <0.001  EGC 0.30 <0.001 
EC 0.24 <0.001  EC 0.22 <0.001 
EGCG 0.21 <0.001  EGCG 0.25 <0.001 
ECG 0.17 <0.001  ECG 0.14 0.04 
Total catechin 0.20 <0.001  Total catechin 0.27 <0.001 
aCategories of plasma tea catechin were defined as 0 for non-detected; 1 through 3 for detected tea catechins divided into tertiles for 
stroke and 1 through 2 for detected tea catechins divided into median for coronary heart disease (CHD). 
EGC: epigallocatechin, EC: epicatechin, EGCG: epigallocatechin-3-gallate, ECG: epicatechin-3-gallate  
 
  
25 
Table 3. Odds ratios (ORs) and 95% confidence intervals (CIs) of stroke and CHD according to plasma tea catechin levels  
Stroke   Men      Women   
   Tertile      Tertile   
 
Non-
detected 
T1 T2 T3 
P for 
trend 
 
Non-
detected 
T1 T2 T3 
P for 
Trend 
EGC (ng/ml)            
 Median a 0.0000 0.0273 0.1498 0.5773   0.0000 0.0301 0.1198 0.4762  
 Median b 0.0000 0.0019 0.0080 0.0352   0.0000 0.0022 0.0077 0.0239  
 No. of cases/no. of controls 315/334 96/82 90/84 82/83   331/341 72/69 81/70 65/69  
 OR (95% CI) c 1.00 1.26(0.90-1.77) 1.15(0.81-1.63) 1.05(0.70-1.57) 0.54  1.00 1.08(0.73-1.60) 1.20(0.82-1.75) 0.96(0.63-1.48) 0.77 
 Multivariate OR (95% CI) d 1.00 1.32(0.91-1.93) 0.99(0.67-1.46) 0.97(0.62-1.51) 1.00  1.00 1.04(0.68-1.60) 1.13(0.75-1.72) 0.95(0.58-1.54) 0.91 
EC (ng/ml)            
 Median a 0.0000 0.0208 0.0563 0.1702   0.0000 0.0168 0.0578 0.1158  
 Median b 0.0000 0.0009 0.0023 0.0111   0.0000 0.0009 0.0021 0.0062  
 No. of cases/no. of controls 324/353 91/76 84/78 84/76   331/338 70/69 76/71 72/71  
 OR (95% CI) c 1.00 1.34(0.94-1.91) 1.25(0.86-1.83) 1.29(0.86-1.94) 0.12  1.00 1.05(0.70-1.56) 1.10(0.75-1.61) 1.05(0.70-1.57) 0.69 
 Multivariate OR (95% CI) d 1.00 1.18(0.80-1.75) 1.13(0.74-1.74) 1.15(0.74-1.79) 0.44  1.00 0.98(0.63-1.52) 0.99(0.65-1.50) 1.02(0.65-1.59) 0.97 
EGCG (ng/ml)            
 Median a 0.0000 0.0281 0.0668 0.1974   0.0000 0.0253 0.0603 0.1434  
 Median b 0.0000 0.0012 0.0027 0.0114   0.0000 0.0011 0.0025 0.0062  
 No. of cases/no. of controls 320/345 108/79 79/80 76/79   337/344 75/68 73/69 64/68  
 OR (95% CI) c 1.00 1.56(1.10-2.21) 1.10(0.76-1.60) 1.04(0.70-1.54) 0.66  1.00 1.13(0.79-1.63) 1.07(0.70-1.64) 0.97(0.64-1.45) 0.98 
 Multivariate OR (95% CI) d 1.00 1.56(1.06-2.29) 0.97(0.64-1.47) 0.83(0.53-1.29) 0.56  1.00 1.07(0.72-1.60) 1.01(0.63-1.62) 0.84(0.53-1.32) 0.57 
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ECG (ng/ml)            
 Median a 0.0000 0.0076 0.0156 0.0359   0.0000 0.0080 0.0161 0.0304  
 Median b 0.0000 0.0015 0.0024 0.0059   0.0000 0.0016 0.0028 0.0059  
 No. of cases/no. of controls 379/390 72/64 81/65 51/64   391/405 64/48 38/48 56/48  
 OR (95% CI) c 1.00 1.19(0.81-1.74) 1.25(0.85-1.84) 0.78(0.49-1.25) 0.96  1.00 1.39(0.92-2.12) 0.82(0.49-1.38) 1.28(0.76-2.14) 0.43 
 Multivariate OR (95% CI) d 1.00 1.21(0.80-1.84) 1.19(0.77-1.84) 0.70(0.42-1.17) 0.60  1.00 1.16(0.73-1.83) 0.84(0.47-1.50) 1.34(0.75-2.39) 0.47 
Total catechin (ng/ml)            
 Median a 0.0000 0.0365 0.2336 0.8745   0.0000 0.0339 0.1696 0.6763  
 Median b 0.0000 0.0016 0.0071 0.0415   0.0000 0.0015 0.0061 0.0282  
 No. of cases/no. of controls 243/261 106/107 118/108 116/107   251/260 101/95 107/97 90/97  
 OR (95% CI) c 1.00 1.09(0.77-1.54) 1.23(0.87-1.73) 1.23(0.84-1.80) 0.42  1.00 1.13(0.80-1.60) 1.17(0.81-1.68) 0.94(0.62-1.43) 0.51 
 Multivariate OR (95% CI) d 1.00 0.98(0.67-1.44) 1.11(0.76-1.61) 1.09(0.72-1.66) 0.72  1.00 1.08(0.73-1.58) 1.09(0.73-1.63) 0.87(0.55-1.40) 0.42 
            
             
CHD  Median    Median  
    
Non-  
detected 
M1 M2 
P for  
trend 
 Non-  
detected 
M1 M2 
P for  
trend 
EGC (ng/ml)          
 Median a 0.0000 0.0728 0.5686   0.0000 0.0471 0.3905  
 Median b 0.0000 0.0141 0.1996   0.0000 0.0127 0.2919  
 No. of cases/no. of controls 64/133 42/66 27/67   40/92 15/30 21/30  
 OR (95% CI) c 1.00 1.35(0.76-2.37) 0.85(0.46-1.60) 0.67  1.00 1.34(0.60-3.00) 2.20(0.93-5.22) 0.08 
 Multivariate OR (95% CI) d 1.00 0.97(0.47-2.00) 0.78(0.35-1.74) 0.55  1.00 1.29(0.52-3.16) 1.99(0.70-5.71) 0.20 
27 
EC (ng/ml)          
 Median a 0.0000 0.0224 0.1304   0.0000 0.0198 0.0723  
 Median b 0.0000 0.0083 0.0467   0.0000 0.0084 0.0512  
 No. of cases/no. of controls 72/140 35/62 26/64   40/86 17/33 19/33  
 OR (95% CI) c 1.00 1.07(0.63-1.84) 0.75(0.40-1.38) 0.42  1.00 1.28(0.58-2.84) 1.49(0.63-3.53) 0.35 
 Multivariate OR (95% CI) d 1.00 1.08(0.54-2.13) 0.96(0.43-2.15) 0.97  1.00 1.26(0.53-3.03) 1.20(0.44-3.28) 0.66 
EGCG (ng/ml)          
 Median a 0.0000 0.0388 0.1386   0.0000 0.0262 0.2238  
 Median b 0.0000 0.0232 0.0679   0.0000 0.0186 0.1034  
 No. of cases/no. of controls 81/165 28/50 24/51   50/103 8/24 18/25  
 OR (95% CI) c 1.00 1.15(0.65-2.06) 0.96(0.52-1.77) 1.00  1.00 0.78(0.32-1.88) 1.71(0.75-3.88) 0.30 
 Multivariate OR (95% CI) d 1.00 0.96(0.46-2.02) 0.95(0.43-2.08) 0.89  1.00 0.55(0.21-1.47) 1.51(0.56-4.05) 0.68 
ECG (ng/ml)          
 Median a 0.0000 0.0119 0.0273   0.0000 0.0057 0.0411  
 Median b 0.0000 0.0067 0.0161   0.0000 0.0045 0.0166  
 No. of cases/no. of controls 76/163 31/51 26/52   43/93 11/28 22/31  
 OR (95% CI) c 1.00 1.43(0.78-2.64) 1.15(0.63-2.09) 0.58  1.00 0.91(0.35-2.41) 1.81(0.79-4.12) 0.16 
 Multivariate OR (95% CI) d 1.00 0.89(0.39-2.00) 0.87(0.40-1.92) 0.73  1.00 0.68(0.22-2.07) 1.52(0.58-4.02) 0.40 
Total catechin (ng/ml)          
 Median a 0.0000 0.1565 0.8830   0.0000 0.0587 0.3414  
 Median b 0.0000 0.0141 0.2703   0.0000 0.0142 0.2251  
 No. of cases/no. of controls 54/113 44/76 35/77   30/70 22/40 24/42  
 OR (95% CI) c 1.00 1.27(0.69-2.34) 1.00(0.51-1.93) 0.57  1.00 1.58(0.71-3.55) 2.01(0.80-5.02) 0.26 
28 
 Multivariate OR (95% CI) d 1.00 1.18(0.53-2.65) 1.02(0.43-2.43) 0.79  1.00 1.69(0.70-4.09) 1.55(0.53-4.48) 0.76 
a Measured at 2004; b Measured at 2008; c Matched for age, sex, date of blood sampling, time since last meal, and study location; d 
Adjusted for systolic blood pressure, anti-hypertensive medication use, diabetes mellitus, body mass index, alcohol intake, smoking 
status, and high-sensitivity C-reactive protein. 
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Table 4. Smoking status specific odds ratios (ORs) and 95% confidence intervals (CIs) of stroke according to plasma tea catechin levels 
in men. 
    Non-smokers      Smokers   
    Tertiles      Tertiles   
    
Non-
detected 
T1 T2 T3 P for trend  
Non-
detected 
T1 T2 T3 
P for 
trend 
EGC (ng/ml)            
 Median a 0.0000 0.0251 0.1712 0.7290   0.0000 0.0281 0.0865 0.5236  
 Median b 0.0000 0.0020 0.0084 0.0319   0.0000 0.0017 0.0073 0.0364  
 No. of cases/no. of controls 168/207 52/52 46/45 23/39   144/120 43/29 44/39 58/44  
 Multivariate OR (95% CI) c 1.00 1.15(0.73-1.82) 1.19(0.72-1.97) 0.68(0.37-1.25) 0.62  1.00 1.43(0.81-2.51) 0.86(0.51-1.46) 1.23(0.74-2.04) 0.65 
EC (ng/ml)            
 Median a 0.0000 0.0224 0.0562 0.2246   0.0000 0.0164 0.0576 0.1637  
 Median b 0.0000 0.0009 0.0021 0.0104   0.0000 0.0009 0.0025 0.0142  
 No. of cases/no. of controls 165/220 62/47 37/37 25/39   156/125 28/29 47/41 58/37  
 Multivariate OR (95% CI) c 1.00 1.62(1.02-2.57) 1.41(0.82-2.43) 0.74(0.40-1.36) 1.00  1.00 0.72(0.39-1.31) 0.88(0.52-1.49) 1.26(0.74-2.15) 0.58 
EGCG (ng/ml)            
 Median a 0.0000 0.0286 0.0799 0.2084   0.0000 0.0277 0.0634 0.1963  
 Median b 0.0000 0.0010 0.0028 0.0118   0.0000 0.0013 0.0027 0.0083  
 No. of cases/no. of controls 168/205 64/54 37/43 20/41   149/133 43/24 42/37 55/38  
 Multivariate OR (95% CI) c 1.00 1.36(0.87-2.13) 0.96(0.57-1.63) 0.53(0.29-0.98) 0.14  1.00 1.77(0.98-3.20) 0.97(0.56-1.67) 1.28(0.75-2.16) 0.47 
ECG (ng/ml)            
30 
 Median a 0.0000 0.0085 0.0152 0.0402   0.0000 0.0071 0.0157 0.0355  
 Median b 0.0000 0.0015 0.0024 0.0059   0.0000 0.0015 0.0024 0.0056  
 No. of cases/no. of controls 202/238 35/37 35/34 17/34   173/146 37/26 46/30 33/30  
 Multivariate OR (95% CI) c 1.00 1.03(0.61-1.76) 1.15(0.67-1.98) 0.53(0.27-1.02) 0.26  1.00 1.26(0.70-2.25) 1.22(0.71-2.09) 1.00(0.55-1.79) 0.70 
Total catechin (ng/ml)            
 Median a 0.0000 0.0349 0.2490 1.0747   0.0000 0.0365 0.1730 0.8601  
 Median b 0.0000 0.0017 0.0064 0.0417   0.0000 0.0016 0.0080 0.0413  
 No. of cases/no. of controls 125/156 57/71 69/62 38/54   115/100 48/33 49/46 77/53  
 Multivariate OR (95% CI) c 1.00 0.92(0.59-1.44) 1.32(0.85-2.05) 0.80(0.48-1.33) 0.34  1.00 1.43(0.83-2.49) 0.91(0.55-1.52) 1.35(0.85-2.15) 0.27 
a Measured at 2004; b Measured at 2008; c Adjusted for systolic blood pressure, anti-hypertensive medication use, diabetes mellitus, 
body mass index, alcohol intake, smoking status, and high-sensitivity C-reactive protein. 
